Papers/PMID:37667938
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.
European review for medical and pharmacological sciences2023The record
3 findings drawn from this paper, on 1 compound across 3 endpoints.
What it reported
How to read these marksWhat moved
3 findings
calciol — decreases C-reactive protein concentration
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results.”
Quoted verbatim from A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.. - Study
- RCT
- Population
- NAFLD patients with type 2 diabetes on standard conventional therapy in both arms; cholecalciferol added in Group 2 vs placebo added in Group 1
calciol — decreases alanine aminotransferase
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results.”
Quoted verbatim from A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.. - Study
- RCT
- Population
- NAFLD patients with type 2 diabetes on standard conventional therapy in both arms; cholecalciferol added in Group 2 vs placebo added in Group 1
calciol — decreases malondialdehyde (circulating)
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results.”
Quoted verbatim from A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.. - Study
- RCT
- Population
- NAFLD patients with type 2 diabetes on standard conventional therapy in both arms; cholecalciferol added in Group 2 vs placebo added in Group 1